ACTHAR Therapy for Central Nervous System Sarcoidosis
Status:
Withdrawn
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
There is a need for a more reliable, expeditious therapy that can be used as an alternative
to glucocorticoids in severe Central Nervous System (CNS) sarcoidosis. This study aims to
provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information
about its safety and tolerability